Overview

Efficacy of Ferric Carboxymaltose (Ferinject®) in Anemic Patients Anticipating Pancreatoduodenectomy

Status:
Completed
Trial end date:
2020-04-27
Target enrollment:
Participant gender:
Summary
This phase II study is to evaluate the safety and efficacy of Ferinject® in reducing perioperative transfusion in iron deficiency anemia patients anticipating pancreatoduodenectomy.
Phase:
Phase 2
Details
Lead Sponsor:
National Cancer Center, Korea
Collaborator:
JW Pharmaceutical
Treatments:
Ferric Compounds